Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations

Richard L. Wasserman

Dallas Allergy Immunology, 7777 Forest Lane, Suite B-332, Dallas, TX 75230, USA

Objective: The availability of weekly subcutaneous infusions of subcutaneous immunoglobulin (SCIg) provides an additional therapeutic option for patients with primary immunodeficiency disease. With proper patient education, individuals can safely transition to SCIg therapy and experience minimal side effects.

Research design: Case reports.

Results: A plan for successful implementation of SCIg therapy is presented. Case reports illustrate the how to manage the transition from IVIg to home infusion of SCIg. In Case 1, despite training, home infusion was complicated by infusion-site reactions, the most common adverse event. Troubleshooting by the medical staff identified improper administration of SCIg, a correctable cause of reactions. In Case 2, patient education enabled this woman to successfully transition to SCIg without adverse effects, and without the headache and fatigue she experienced with IVIg.

Conclusions: Home infusion of SCIg can be successfully implemented with careful planning, patient/caregiver education, support, and follow-up.

Keywords: immunodeficiency, primary, IgG deficiency, therapy, immunoglobulins, IV, subcutaneous, adverse effects